Literature DB >> 23942048

Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells.

Tung-Ying Lu1, Bo Lin, Jong Kim, Mara Sullivan, Kimimasa Tobita, Guy Salama, Lei Yang.   

Abstract

Heart disease is the leading cause of death in the world. Heart tissue engineering holds a great promise for future heart disease therapy by building personalized heart tissues. Here we create heart constructs by repopulating decellularized mouse hearts with human induced pluripotent stem cell-derived multipotential cardiovascular progenitor cells. We show that the seeded multipotential cardiovascular progenitor cells migrate, proliferate and differentiate in situ into cardiomyocytes, smooth muscle cells and endothelial cells to reconstruct the decellularized hearts. After 20 days of perfusion, the engineered heart tissues exhibit spontaneous contractions, generate mechanical force and are responsive to drugs. In addition, we observe that heart extracellular matrix promoted cardiomyocyte proliferation, differentiation and myofilament formation from the repopulated human multipotential cardiovascular progenitor cells. Our novel strategy to engineer personalized heart constructs could benefit the study of early heart formation or may find application in preclinical testing.

Entities:  

Mesh:

Year:  2013        PMID: 23942048     DOI: 10.1038/ncomms3307

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  116 in total

1.  Hepatocytic differentiation of iPS cells on decellularized liver tissue.

Authors:  Mitsuhi Hirata; Tetsuji Yamaoka
Journal:  J Artif Organs       Date:  2017-08-03       Impact factor: 1.731

Review 2.  Cardiovascular Tissue Engineering: Preclinical Validation to Bedside Application.

Authors:  Cameron Best; Ekene Onwuka; Victoria Pepper; Malik Sams; Jake Breuer; Christopher Breuer
Journal:  Physiology (Bethesda)       Date:  2016-01

Review 3.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

4.  Engineered heart slices for electrophysiological and contractile studies.

Authors:  Adriana Blazeski; Geran M Kostecki; Leslie Tung
Journal:  Biomaterials       Date:  2015-04-17       Impact factor: 12.479

Review 5.  Repopulation of decellularized whole organ scaffold using stem cells: an emerging technology for the development of neo-organ.

Authors:  Aleem Ahmed Khan; Sandeep Kumar Vishwakarma; Avinash Bardia; J Venkateshwarulu
Journal:  J Artif Organs       Date:  2014-07-17       Impact factor: 1.731

6.  In vitro comparative study of two decellularization protocols in search of an optimal myocardial scaffold for recellularization.

Authors:  Isaac Perea-Gil; Juan J Uriarte; Cristina Prat-Vidal; Carolina Gálvez-Montón; Santiago Roura; Aida Llucià-Valldeperas; Carolina Soler-Botija; Ramon Farré; Daniel Navajas; Antoni Bayes-Genis
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 7.  Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming.

Authors:  I K Rony; A Baten; J A Bloomfield; M E Islam; M M Billah; K D Islam
Journal:  Cell Prolif       Date:  2015-01-29       Impact factor: 6.831

8.  Tissue engineering toward organ-specific regeneration and disease modeling.

Authors:  Christian Mandrycky; Kiet Phong; Ying Zheng
Journal:  MRS Commun       Date:  2017-07-31       Impact factor: 2.566

Review 9.  Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.

Authors:  Shi Hua Tan; Lei Ye
Journal:  J Cardiovasc Transl Res       Date:  2018-03-19       Impact factor: 4.132

Review 10.  Fibrous scaffolds for building hearts and heart parts.

Authors:  A K Capulli; L A MacQueen; Sean P Sheehy; K K Parker
Journal:  Adv Drug Deliv Rev       Date:  2015-12-04       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.